Monkey pox — a serious threat or not, and what about EMS?

Pruc, Michał; Chirico, Francesco; Navolokin, Ihor; Szarpak, Łukasz

doi:10.5603/demj.a2022.0022

Cited by 5 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The scars may last for years. Mpox is transmissible from the start of symptoms until the rash is healed and replaced with a new layer of skin 13,14…”

Section: Transmission and Etiologymentioning

confidence: 99%

Mpox (monkeypox)

Jarrell

Perryman

2023

The Nurse Practitioner

View full text Add to dashboard Cite

:Mpox (formerly “monkeypox”) is a viral zoonosis that presents similarly to smallpox but is less contagious and causes less severe disease. Mpox may be transmitted from infected animals to humans through direct contact or a scratch or bite. Human-to-human transmission occurs through direct contact, respiratory droplets, and fomites. Two vaccines, JYNNEOS® and ACAM2000®, are currently available for postexposure prophylaxis as well as for prevention in certain populations at high risk for mpox. Most cases of mpox are self-limited; however, tecovirimat, brincidofovir, and cidofovir are available as treatments for at-risk populations.

show abstract

“…The scars may last for years. Mpox is transmissible from the start of symptoms until the rash is healed and replaced with a new layer of skin 13,14…”

Section: Transmission and Etiologymentioning

confidence: 99%

Mpox (monkeypox)

Jarrell

Perryman

2023

The Nurse Practitioner

View full text Add to dashboard Cite

show abstract

“…Tecovirimat (TPOXX, ST‐246), a low‐molecular‐weight antiviral drug, is the first FDA‐approved treatment for smallpox treatment in adults and pediatrics weighing ≥13 kg 16,17 . Tecovirimat has been licensed for the treatment of mpox in the European Union and the US 18 . It inhibits orthopoxvirus replication by inhibiting the p37 envelope protein 19,20 .…”

Section: Tecovirimatmentioning

confidence: 99%

“… 16 , 17 Tecovirimat has been licensed for the treatment of mpox in the European Union and the US. 18 It inhibits orthopoxvirus replication by inhibiting the p37 envelope protein. 19 , 20 The details of the molecular mechanism of action of tecovirimat are shown in Figure 1 .…”

Section: Tecovirimatmentioning

confidence: 99%

Clinical considerations on monkeypox antiviral medications: An overview

Pourkarim,

Entezari‐Maleki

2023

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Monkeypox (mpox), a virus belonging to the orthopoxvirus family, can cause a zoonotic infectious disease with morbidity and cosmetic complications. Therefore, effective antiviral drugs with appropriate safety profiles are important for the treatment of patients with mpox. To date, there is no FDA‐approved drug for the treatment of mpox. However, tecovirimat, brincidofovir, and cidofovir are the candidate therapies for the management of mpox. Given the safety concerns following the use of these medications, we aimed to review evidence on the clinical considerations of mpox antiviral medications that will be useful to guide clinicians in the treatment approach. Based on the current evidence, tecovirimat has favorable clinical efficacy, safety, and side effect profile and it can be considered as first‐line treatment for mpox.

show abstract

“…Two vaccines have been tested to this effect, JYNNEOS™ and ACAM2000®, both of which have been shown to have a protective effect against Monkeypox virus [5] . There is also work underway for a vaccine specifically against Monkeypox [6] . Similarly, there is evidence that several pharmacological interventions approved for use against smallpox may be effective anti-virals to treat Monkeypox.…”

mentioning

confidence: 99%